Acurx Pharmaceuticals ACXP
Jump To Section
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Acurx Pharmaceuticals (ACXP)
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
Key Insights
Critical company metrics and information
Latest Closing Price
$0.4573Market Cap
$8.93 MillionPrice-Earnings Ratio
-0.42Total Outstanding Shares
19.53 Million SharesTotal Employees
4Dividend
No dividendIPO Date
June 25, 2021SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockHeadquarters
259 liberty avenue, Staten island, NY, 10305Homepage
https://www.acurxpharma.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $0 |
Net Cash Flow From Financing Activities | $11.04 Million |
Net Cash Flow | $0 |
Net Cash Flow From Investing Activities | $1.29 Million |
Net Cash Flow From Investing Activities, Continuing | $1.29 Million |
Net Cash Flow From Operating Activities | $-12.33 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Operating Expenses | $16.44 Million |
Net Income/Loss Attributable To Parent | $-16.44 Million |
Diluted Earnings Per Share | $-1.09 |
Net Income/Loss | $-16.44 Million |
Income/Loss From Continuing Operations Before Tax | $-16.44 Million |
Research and Development | $6.52 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Comprehensive Income/Loss | $-16.44 Million |
Comprehensive Income/Loss Attributable To Parent | $-16.44 Million |
Other Comprehensive Income/Loss | $0 |
Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Current Liabilities | $3.32 Million |
Assets | $5.98 Million |
Current Assets | $5.98 Million |
Prepaid Expenses | $122,822 |
Liabilities | $3.32 Million |
Equity Attributable To Noncontrolling Interest | $0 |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Recent Headlines From The Web
Latest news, press releases, and media coverage about ACXP from trusted financial sources
Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2025 Financhle. All Rights Reserved.